Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma;Interdisziplinäre therapieempfehlungen zur behandlung des hormonrefraktären prostatakarzinoms

Aktuelle Urologie

Volumn 37, Issue 3, 2006, Pages 201-204

  Miller, K ^a,a   Becker, K ^a   Finke, F ^a   Geiges, G ^a   Gockel Beining B ^a   Hossfeld, D K ^a   Osieka, R ^a   Russel C ^a   Tesch, H ^a   Weissbach L ^a   Wirth, M ^a   Wolff, J M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chemotherapy; Hormone refractory prostatic carcinoma; Interdisciplinary recommendation for therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DOCETAXEL; TAXOID;

CONSENSUS DEVELOPMENT; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG RESISTANCE; HUMAN; MALE; PATIENT CARE; PRACTICE GUIDELINE; PROSTATE TUMOR; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PATIENT CARE TEAM; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 33746868362     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-932205     Document Type: Review

References (8)

1. Ryan CJ, Small EJ. Secondary hormonal manipulations in prostate cancer. Curr Oncol Rep 2005; 7 (3): 228-233
2. Morote J et al. Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. Int J Biol Markers 2005; 20 (2): 119-122
3. Tannock IF et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512
4. Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513-1520
5. Kojima S et al. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004; 171 (2 Pt 1): 679-683
6. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11 (11): 2167-2172
7. Hussain M et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12 (9): 1868-1875
8. Roessner R et al. Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer. J Clin Oncol 2005; Abstr. No 4554